wherein the weight ratio of said fine particles to said coarse particles is 5:95 to 30:70; and

(B) micronized particles of glycopyrronium bromide, formoterol fumarate dihydrate, and, optionally, beclometasone dipropionate, as active ingredients,

wherein said formulation is obtainable by a process comprising:

(i) mixing said carrier, said formoterol fumarate dihydrate, and, optionally, said beclometasone dipropionate in a vessel of a shaker mixer at a speed of rotation not lower than 16 r.p.m. for a time of not less than 60 minutes, to obtain a first mixture; and

(ii) adding said glycopyrronium bromide to said first mixture, to obtain a second mixture, and mixing said second mixture at a speed of rotation not higher than 16 r.p.m. for a time of not more than 40 minutes; and whereby the mid fine particle fraction of glycopyrronium bromide is higher than 25%.

12. The powder according to claim 11, wherein the process further comprises:

(iii) further mixing the formulation obtained in (ii), to achieve a homogeneous distribution of said active ingredients

13. The powder formulation according to claim 11 or 12, wherein the mid fine particle fraction is comprised between 28 and 40%.

14. The powder formulation according to any one of claims 11 to 13, wherein the physiologically acceptable excipient is alpha-lactose monohydrate.

15. The powder formulation according to any one of claims 11 to 14, wherein the coarse particles have a mass diameter comprised between 210 and 360 μm.

16. A dry powder inhaler device filled with the dry powder formulation of any one of claims 11 to 15.

17. The dry powder formulation of any one of claims 11 to 15 for use for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

18. The dry powder formulation of claim 17, wherein the disease is asthma or chronic obstructive pulmonary disease (COPD).

19. Use of the dry powder formulation of any one of claims 11 to 15 in the manufacture of a medicament for the prevention and/or treatment of an inflammatory and/or obstructive airways disease.

20. The use according to claim 19, wherein the disease is asthma or chronic obstructive pulmonary disease (COPD).